NASDAQ:DBVT - DBV TECHNOLOGIE/S Stock Price, Forecast & News

DBV TECHNOLOGIE/S trades on the NASDAQ under the ticker symbol "DBVT."

DBV TECHNOLOGIE/S (NASDAQ:DBVT) announced its earnings results on Thursday, March, 26th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.35. View DBV TECHNOLOGIE/S's Earnings History.

DBV TECHNOLOGIE/S is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for DBV TECHNOLOGIE/S.

6 brokerages have issued 1-year price targets for DBV TECHNOLOGIE/S's shares. Their forecasts range from $14.00 to $25.00. On average, they expect DBV TECHNOLOGIE/S's share price to reach $18.20 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price. View Analyst Price Targets for DBV TECHNOLOGIE/S.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV TECHNOLOGIE/S in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DBV TECHNOLOGIE/S.

News coverage about DBVT stock has been trending somewhat negative on Sunday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DBV TECHNOLOGIE/S earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for DBV TECHNOLOGIE/S.

Some companies that are related to DBV TECHNOLOGIE/S include Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Audentes Therapeutics (BOLD), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Bill.com (RVMD), Cortexyme (CRTX), Coherus Biosciences (CHRS), SpringWorks Therapeutics (SWTX) and Editas Medicine (EDIT).

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV TECHNOLOGIE/S investors own include Aimmune Therapeutics (AIMT), Bellicum Pharmaceuticals (BLCM), Immunomedics (IMMU), Exelixis (EXEL), Pieris Pharmaceuticals (PIRS), Fate Therapeutics (FATE), Five Prime Therapeutics (FPRX), Heron Therapeutics (HRTX), Sangamo Therapeutics (SGMO) and Pfizer (PFE).

DBV TECHNOLOGIE/S's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (6.99%), ArrowMark Colorado Holdings LLC (4.92%), Perceptive Advisors LLC (4.78%), First Midwest Bank Trust Division (0.64%), Syquant Capital Sas (0.47%) and Artisan Partners Limited Partnership (0.41%).

DBVT stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, UBS Group AG and Goldman Sachs Group Inc..

DBVT stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Perceptive Advisors LLC, ArrowMark Colorado Holdings LLC, Syquant Capital Sas, Marshall Wace LLP, Bailard Inc., Ikarian Capital LLC and Premier Asset Management LLC.

Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DBVT stock can currently be purchased for approximately $9.93.

DBV TECHNOLOGIE/S has a market capitalization of $906.41 million and generates $17.17 million in revenue each year. The company earns $-196,140,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis. DBV TECHNOLOGIE/S employs 244 workers across the globe.View Additional Information About DBV TECHNOLOGIE/S.

The official website for DBV TECHNOLOGIE/S is http://www.dbv-technologies.com/.

DBV TECHNOLOGIE/S's mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78 or via email at [email protected]